Statistical Insights

By Aiden Flynn, Exploristics CEO

Drug developers running clinical trials face many challenges. However, a common pain point is recruitment. This can particularly bite when the studies involved are evaluating therapies for diseases where there are small populations or where …

By Kim Hacquoil, Exploristics CDSO

In our daily lives, we’re constantly faced with choices that impact our future. Some of these decisions may be relatively small, low impact ones like picking a restaurant for dinner or which film to watch. …

By Aiden Flynn, Exploristics CEO

I recently went to see an outstanding and thought-provoking play called Dr Semmelweiss in London’s West End.  It is a true story based on the life of Ignaz Philipp Semmelweis, a Hungarian obstetrician and scientist …

By Kimberley Hacquoil, Exploristics CDSO

Earlier this year, the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) released a draft revision to their most widely recognised E6 guideline (ICH E6(R3)).  The overarching …

By Aiden Flynn, CEO at Exploristics

We are regularly approached by growing biotechnology companies for biostatistical support. Often, these companies either have no in-house statistical capability or only a single statistician. Understanding how best to support their needs got me …

By Kim Hacquoil, Exploristics CDSO

It is not possible for clinical trials to test investigational treatments on all potential patients. Therefore, clinical trials are conducted on a sample of participants drawn from the population of interest. The results of a …

By Aiden Flynn. Exploristics CEO

Successful clinical trials depend on people participating in them. For participants this means, opting in and staying the course even while in some cases being very ill. However, for those that sign up, they often …